



ASX Announcement

27 October 2022

Corporate Travel Management Managing Director AGM Presentation and Trading Update

Corporate Travel Management (CTM, ASX:CTD) will today present the attached presentation and trading update at its Annual General Meeting. A copy of the Managing Director's presentation is attached.

Authorised for release by Shelley Sorrenson, Company Secretary.

Contact details

Media enquiries: Alasdair Jeffrey - Rowland: Alasdair.Jeffrey@rowland.com.au / +61 404 926 768

Investor enquiries: Allison Dodd - allison.dodd@travelctm.com / +61 7 3210 3354

AUSTRALIA | NEW ZEALAND | NORTH AMERICA | ASIA | EUROPE

Corporate Travel Management Limited ABN: 17 131 207 611
Level 24, 307 Queen Street, Brisbane, QLD 4000 GPO Box 2584, Brisbane, QLD 4001
Telephone: +61 7 3211 2400 Fax: +61 7 3236 1930 Free call: 1800 663 622
info@travelctm.com www.travelctm.com



FY22 Highlights

CTM FY22 highlights

Successfully converting activity recovery into revenue and PBT

- **FY22:** TTV \$5.1bn, revenue \$389m, underlying: EBITDA \$59.8m, PBT \$22.3m, NPAT \$17.5m
- **4Q22:** TTV \$1.8bn, revenue \$141m, underlying: EBITDA \$35.7m, PBT \$25.5m, NPAT \$20.5m

Strong 4Q22 momentum

Starting run rate for FY23 (4Q22 annualised):

- **Revenue \$563m; underlying: EBITDA \$143m, PBT \$102m**
- June revenue materially higher than April
- 4Q22: 14% productivity gains

Financial Strength

- **\$127m corporate cash, zero debt**, positive PBT, strong cash flow, adequate working capital
- **Reinstated dividends:** 5c final dividend (unfranked) paid with future intention to pay 50% of NPAT

Recovering faster than market - winning share

- Strong market share gains as evidenced by **revenue recovery** @ 69.5% in 4Q22
- Value proposition, global scale, financial strength all highly relevant to clients – **97% client retention**
- Enhancing proprietary automation and RPA tools to enhance service expertise in FY23

A 75% larger business that is expected to deliver record EPS on full recovery

- Full recovery to deliver revenue \$810m, underlying EBITDA \$265m, up c75% on FY19 (pre-COVID)
- Capital raised during COVID has enabled highly accretive acquisitions, full recovery expected to deliver 30%+ EPS growth on FY19 EPS (pre-COVID)



Trading Update



Trading update: General market insights

Observation	Outcome
1. Removal of travel impediments drives rapid recovery in corporate activity	<ul style="list-style-type: none">• Experiencing rapid recovery when COVID related impediments removed
2. Airline reliability and airport experience impacting corporate activity recovery	<ul style="list-style-type: none">• Where airline reliability and airport congestion is near normal, corporate travel activity now above pre-COVID pro-forma levels (FY19)• Where airport congestion and airline unreliability exists, recovery temporarily stalls until resolved
3. Corporate travel demand remains strong. Inadequate airline capacity persists	<ul style="list-style-type: none">• Supply unable to keep up with corporate demand. Airline capacity constraints holding back faster recovery• Average booking completion time higher than pre-COVID due to higher airline disruption management, finding available seats, clearing waitlists, creative trip planning.• Both issues progressively resolving week by week as global network rebuilds
4. No noticeable impact of economic conditions upon activity	<ul style="list-style-type: none">• September revenue recovery at 75% of pro-forma pre-COVID• ANZ and EU regions, Singapore already above pre-COVID pro-forma trading levels in September despite greatly reduced capacity, reinforcing strong market share gains through COVID period• Further revenue recovery, some regions significant, across October v September

Regional trading update: FY23 year-to-date

Region	September activity ¹	October month-to-date ²	Update
EU	101%	↑	<ul style="list-style-type: none"> Still to come: international, domestic UK and UK government as people return to work Heathrow airport announced lifting capacity to 100% (from 80%) end of October
ANZ	116%	↑	<ul style="list-style-type: none"> Revenue recovery to 85% in September as international recovery increases Upside to come: BNE-SYD-MEL triangle capacity constraints c70%, international supply c45% of pre-Covid, HLO synergies
Asia	51%	↑↑	<ul style="list-style-type: none"> Pre-Covid, HKG/SIN represented 90% of Asia revenue: <ul style="list-style-type: none"> September: Singapore trading >100% pre-Covid pro-forma FY19 levels HKG: removal of hotel quarantine 27 September; rapid recovery only limited by supply. HKG recovery >3x Cathay Pacific Airline capacity recovery- a market share gain signal
NA	70%	Steady	<ul style="list-style-type: none"> Activity post-vacation back to peaks of April/May despite small decline in average ticket value Slower than expected post-vacation September recovery vs RoW. Airline disruption/poor airport experience lingers, impacting demand for short duration travel Expect activity to accelerate with greater airline reliability, consistent with all other CTM regions 80% revenue recovery a stepped change to regional profitability as we soak up excess workforce capacity employed in May, leverage integration and scale benefits

¹ Activity vs proforma pre-COVID 2019 (FY19)

² Activity growth vs September 2022

Group trading update: outlook

Group	Update
Activity summary	<ul style="list-style-type: none"> • No noticeable impact from economic conditions • Consistent theme: demand for corporate travel exceeding supply, travel rebounds rapidly with travel impediment removal & reliability in airline and airport experience • Further material recovery levers: supply constraints, client recovery, synergy & scale benefits, organic growth • Two regions already surpassed pro-forma FY19 despite constraints, reinforcing CTM market share gains
Workforce recovery	<ul style="list-style-type: none"> • Staff count (FTE) at 30 September: 2956 (+102 since 30 June, predominantly ANZ region) • Workforce build out now largely complete in all CTM regions ex HKG • Graduate academy being rolled out in all regions due to success in ANZ region
Financial metrics	<p>Revenue and FY23 profit skew:</p> <ul style="list-style-type: none"> • 1Q typically the slowest profit quarter due to seasonality of northern hemisphere vacation (Jul-Aug) • September TTV c\$0.8bn, an all-time CTM record • September revenue recovery 75%, October tracking higher than September • Consensus requires c80% revenue recovery across FY23 • CTM expects a similar 1H profit skew to FY22, c30%/70%, on-track
Market share gains	<p>Continues at an accelerated rate:</p> <ul style="list-style-type: none"> • Client wins at all-time record levels through to mid-October - surpassed CTM's largest ever full FY result • Client retention remains >97%
Balance sheet strength, scale	<ul style="list-style-type: none"> • Zero debt, significant cash holdings building since 30 June 2022 consistent with 1Q23 profit generation • CTM is already a much larger business than pre-COVID (FY19) • Expecting to be 75% larger than FY19 at full recovery

FY23-24 Assumptions


FY23 Assumptions:

- Starting point is underlying EBIDA \$143m (4Q22 run-rate)
- Targeting c80% revenue recovery in FY23
- FY23 expected to remain choppy:
 - Supply constraints/airport congestion lingers, notably USA
 - Greater China largely closed (Asia full recovery contributes ~\$25m EBITDA)
 - Expect both issues to resolve progressively during FY23
- No further impact on activity from economic conditions than currently experiencing
- COVID remains endemic

FY24 – full recovery (underlying EBITDA \$265m on \$810m revenue) if:

- Greater China to open borders with no travel impediments by June 2023
- Supply constraints/airport congestion resolved in all CTM markets by June 2023

Revenue and underlying EBITDA recovery to FY24 (A\$m)



- ① **FY19-** Record CTM Revenue and EBITDA (pre-COVID)
- ② **Recovery phase begins.** Every additional \$1 revenue translating into 50c of EBITDA
- ③ **Current position** - 4Q22 annualised revenue recovered to 69.5% of FY24 target
- ④ **FY24:** Full recovery expectations: revenue \$810m, underlying EBITDA \$265m, 50% incremental EBITDA margin

² FY23/24 Forecast